Dr. Etienne joined Targanta (then PhageTech) in June 2003 at a time when the company was solely focused on leveraging its phage-bacteria platform to create new antibiotic chemical series. From 1996 to 2003, Dr. Etienne was a senior executive in Pfizer Worldwide Development Operations, accountable for the clinical execution of all Phase 2 and Phase 3 trials in addition to leading a virtual small company focused on the development of prescription botanical products for Pfizer. From 1989 to 1992, he led the experimental medicine group at Pfizer US Laboratories in Groton, CT and the entire US early clinical research group from 1992 to 1996. Dr. Etienne holds an M.D. degree from Univerist� de Li�ge, Belgium, and trained in neurochemistry and psychiatry at McGill University in Montreal. Before joining industry he was chief investigator on an MRC (Canada) program grant on the cholinergic hypothesis of Alzheimer�s disease. Over his professional career, Dr. Etienne has developed significant experience in academic-industrial relations, the transition of compounds from the pre-clinical to the clinical stage, their early characterization and their valuation. He also has acquired a significant world expertise in the execution of trials for registration in the US, Europe and Japan. Dr. Etienne is a director of ESVEE Pharmaceuticals, Private Limited in Pune, India and a principal of Decision Options, LLC in Groton, CT. Dr. Etienne sits on the scientific advisory boards of Neuro-3D, in Mulhouse, France, of Enobia, in Montreal Canada and he also sits on the development council of Neurogen, Inc. in Branford, CT.